Programs

Surrozen is developing a broad pipeline of disease-specific antibodies to help gravely ill patients across multiple disease areas.

Our strategy is to harness the full breadth of Wnt potential by identifying disease states responsive to Wnt pathway modulation, design tissue-specific antibodies, and advance candidates into clinical development in indications with high unmet need.

The following table highlights our lead programs.

Lead Programs

Indication(s)

Research

Preclinical

Phase 1

Phase 2

Phase 3

Indication

Status / Upcoming Milestones

Regulatory

Next Milestone

SZN-1326
Moderate to Severe IBD
Initiated clinical trial Q2’22
Initiated clinical trial Q2’22
SZN-043
Severe Alcoholic Hepatitis
Initiated clinical trial Q2’22
Initiated clinical trial Q2’22


The following table highlights our identified research programs.

Research Programs

Tissue

Indications

Discovery

Proof of Concept

Lead Candidate/s

Status

Cornea
Fuchs' Dystrophy, Limbal Cell Deficiency
Discovery
RPE
Dry AMD
Discovery
Lacrimal Gland
Severe Dry Eye (Sjögren’s)
Discovery
Intestine
Short Bowel Syndrome
Discovery
Cochlea
Hearing Loss
Discovery
Lung
IPF, COPD
Discovery
Renal
Polycystic Kidney Disease, FSGS
Discovery

IBD: Inflammatory Bowel Disease; AMD: Age-related Macular Degeneration; RPE: Retinal Pigment Epithelium; IPF: Idiopathic Pulmonary Fibrosis; COPD: Chronic Obstructive Pulmonary Disease; FSGS: Focal Segmental Glomerulosclerosis; DME: Diabetic Macular Edema

Surrozen’s novel approach to modulating the Wnt pathway may lead to therapeutics that reverse the effects of serious diseases by repairing damaged tissue, restoring organ function and renewing a patient’s health, and hope, for an improved quality of life.

Repair. Restore. Renew.